Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

编者按： 2024年欧洲肿瘤内科学会（ESMO）年会于当地时间9月13日~17日在西班牙巴塞罗那召开。作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学大咖，为全球学者提供了良好的交流平台。今年， 复旦大学附属肿瘤医院叶定伟教授团队 ...

为何EGFR/HER3双抗在尿路上皮癌中表现出出色的疗效信号，对于其分子机制的探索还有很长的路要走。从目前已知的机制来说：EGFR和HER3在膀胱癌中具有很高的表达率，且EGFR与HER3的激活或突变与肿瘤发展、耐药等密切相关。

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

This is the first comprehensive immunohistochemical analysis of the expression of several class I HDAC proteins (1, 2 and 3) in urothelial carcinoma. In our study, we found all three isoforms in a ...

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that three abstracts on BL-B01D1, a ...